

Nerve growth factor inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/NB1EE4AB603AEN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: NB1EE4AB603AEN

Abstracts

This report can be delivered to the clients within 24 hours

DelveInsight's, "Nerve growth factor inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Nerve growth factor inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Nerve growth factor inhibitors Understanding

Nerve growth factor inhibitors: Overview

Nerve growth factor (NGF) is an insulin-like protein, which regulates growth, development and maintenance of sympathetic and embryonic sensory neurons.

Function - NGF is involved primarily in the growth, as well as the maintenance, proliferation, and survival of nerve cells (neurons). In fact, NGF is critical for the survival and maintenance of sympathetic and sensory neurons, as they undergo apoptosis in its absence. However, several recent studies suggest that NGF is also involved in pathways besides those regulating the life cycle of neurons.

Nerve growth factor inhibitors - NGF is involved in pain signalling. The exact role of

NGF signalling in chronic pain is not fully understood, and multiple mechanisms are thought to be involved. NGF is released by immune cells in response to peripheral injury, and is thought to promote neural sensitisation, and neural sprouting. Elevated NGF levels are seen in those with chronic pain conditions (including interstitial cystitis, prostatitis, arthritis, pancreatitis, chronic headaches, cancer pain, and diabetic neuropathy, and injection of NGF causes allodynia and hyperalgesia. NGF inhibitors may take the form of monoclonal antibodies that bind to NGF, or small molecule inhibitors of NGF receptors. NGF inhibition may be achieved by sequestering free NGF molecules, blocking receptor binding, or inhibiting receptor function. Anti-NGF antibodies have demonstrated the greatest promise as potential medications.

Nerve growth factor inhibitors Emerging Drugs Chapters

This segment of the Nerve growth factor inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nerve growth factor inhibitors Emerging Drugs

Tanezumab: Eli Lilly and Company

Tanezumab is an investigational humanized monoclonal antibody, which works by selectively targeting, binding to and inhibiting NGF. NGF levels increase in the body as a result of injury, inflammation or in chronic pain states. By inhibiting NGF, tanezumab may help to keep pain signals produced by muscles, skin and organs from reaching the spinal cord and brain. Tanezumab has a novel mechanism that acts in a different manner than opioids and other analgesics, including nonsteroidal anti-inflammatory drugs (NSAIDs). Currently, it is in preregistration stage for the treatment of Musculoskeletal pain.

Fasinumab: Mirati Therapeutics

Fasinumab, a recombinant, fully human, selective anti-nerve growth factor (NGF) monoclonal antibody, is being developed by Regeneron Pharmaceuticals in collaboration with Mitsubishi Tanabe Pharma. Currently, it is in phase III stage of

development for the treatment of Musculoskeletal pain.

Further product details are provided in the report.....

Nerve growth factor inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Nerve growth factor inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Nerve growth factor inhibitors

There are approx. 4+ key companies which are developing the Nerve growth factor inhibitors. The companies which have their Nerve growth factor inhibitors drug candidates in the most advanced stage, i.e. preregistration include, Eli Lilly and Company.

Phases

DelveInsight's report covers around 4+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Nerve growth factor inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under

various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and

Mono/Combination.

Nerve growth factor inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nerve growth factor inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nerve growth factor inhibitors drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Nerve growth factor inhibitors R&D. The therapies under development are focused on novel approaches for Nerve growth factor inhibitors.

Nerve growth factor inhibitors Report Insights

Nerve growth factor inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Nerve growth factor inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Nerve growth factor inhibitors drugs?

How many Nerve growth factor inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Nerve growth factor inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Nerve growth factor inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Nerve growth factor inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Eli Lilly and Company

Mitsubishi Tanabe Pharma

Regeneron Pharmaceuticals

Spine Biopharma

Ensol Biosciences

Astellas Pharma

Key Products

Tanezumab

Fasinumab

YH 14618

Engedi 1000

ASP 6294

Contents

Introduction

Executive Summary

Nerve growth factor inhibitors: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Nerve growth factor inhibitors – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Nerve growth factor inhibitors companies' collaborations, Licensing, Acquisition -Deal

Value Trends

Nerve growth factor inhibitors Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Pre-registration)

Comparative Analysis

Tanezumab: Eli Lilly and Company

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Engedi 1000: Ensol Biosciences

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Nerve growth factor inhibitors Key Companies

Nerve growth factor inhibitors Key Products

Nerve growth factor inhibitors- Unmet Needs

Nerve growth factor inhibitors- Market Drivers and Barriers

Nerve growth factor inhibitors- Future Perspectives and Conclusion

Nerve growth factor inhibitors Analyst Views

Nerve growth factor inhibitors Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Nerve growth factor inhibitors

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Nerve growth factor inhibitors
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Nerve growth factor inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/NB1EE4AB603AEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NB1EE4AB603AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970